Lexaria Bioscience (Lexaria Bioscience) Days Payable : 0.00 (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Days Payable?

Lexaria Bioscience's average Accounts Payable for the three months ended in Feb. 2024 was $0.07 Mil. Lexaria Bioscience's Cost of Goods Sold for the three months ended in Feb. 2024 was $0.00 Mil.

The historical rank and industry rank for Lexaria Bioscience's Days Payable or its related term are showing as below:

LEXX' s Days Payable Range Over the Past 10 Years
Min: 81.59 Med: 462.68 Max: 6310.44
Current: 6310.44

During the past 13 years, Lexaria Bioscience's highest Days Payable was 6310.44. The lowest was 81.59. And the median was 462.68.

LEXX's Days Payable is ranked better than
93.98% of 714 companies
in the Biotechnology industry
Industry Median: 146.16 vs LEXX: 6310.44

Lexaria Bioscience's Days Payable declined from Feb. 2023 (6,250.63) to Feb. 2024 (0.00). It may suggest that Lexaria Bioscience accelerated paying its suppliers.

Lexaria Bioscience Days Payable Historical Data

The historical data trend for Lexaria Bioscience's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Days Payable Chart

Lexaria Bioscience Annual Data

Trend

Oct13

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Days Payable

Get a 7-Day Free Trial

357.07

81.59

108.88

462.68

2,031.05

Lexaria Bioscience Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Days Payable	Get a 7-Day Free Trial															6,250.63	4,179.95	-	2,892.63	-

Competitive Comparison of Lexaria Bioscience's Days Payable

For the Biotechnology subindustry, Lexaria Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Days Payable distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Days Payable falls into.

Lexaria Bioscience Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Lexaria Bioscience's Days Payable for the fiscal year that ended in Aug. 2023 is calculated as

	Days Payable (A: Aug. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Aug. 2022 )	+	Accounts Payable (A: Aug. 2023 ))	/	count )	/	Cost of Goods Sold (A: Aug. 2023 )	*	Days in Period
=	( (0.12	+	0.225)	/	2 )	/	0.031	*	365
=	0.1725					/	0.031	*	365
=	2,031.05

Lexaria Bioscience's Days Payable for the quarter that ended in Feb. 2024 is calculated as:

	Days Payable (Q: Feb. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Nov. 2023 )	+	Accounts Payable (Q: Feb. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Feb. 2024 )	*	Days in Period
=	( (0.092	+	0.048)	/	2 )	/	0	*	365 / 4
=	0.07					/	0	*	365 / 4
=	N/A

Lexaria Bioscience Days Payable Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Executives

Catherine C. Turkel	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey	officer: Chief Financial Officer	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka	director, 10 percent owner, officer: CEO	1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle	officer: Secretary	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr	director
Brian W. Quigley	director	100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie	director	305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger	officer: CFO	8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty	director, 10 percent owner	23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar	director, officer: CFO	604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter	director	220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford	director	888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke	officer: Sr. VP, Business Development	38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini	director, 10 percent owner	11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan	director, officer: Vice President - Corp Develop	SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6